ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: SA-PO898

eGFR Changes in Uncontrolled Gout Patients Randomized to Receive Methotrexate or Placebo as Co-Therapy to Pegloticase: MIRROR RCT Findings

Session Information

Category: CKD (Non-Dialysis)

  • 2202 CKD (Non-Dialysis): Clinical‚ Outcomes‚ and Trials


  • Abdellatif, Abdul A., Baylor College of Medicine, Houston, Texas, United States
  • Botson, John K., Orthopedic Physicians Alaska, Anchorage, Alaska, United States
  • Obermeyer, Katie L., Horizon Therapeutics plc, Deerfield, Illinois, United States
  • LaMoreaux, Brian, Horizon Therapeutics plc, Deerfield, Illinois, United States
  • Marder, Brad Allan, Horizon Therapeutics plc, Deerfield, Illinois, United States

The MIRROR RCT trial (methotrexate [MTX] or placebo [PBO] co-therapy to pegloticase) showed increased urate-lowering response rate (71.0% vs 38.5% during Month 6) and lower infusion reaction rate (4% vs 31%) in patients (pts) co-administered MTX. Because CKD is prevalent in gout pts and MTX is used cautiously in CKD pts, pegloticase+MTX co-therapy impact on renal function is of interest. Here we report eGFR changes in MIRROR RCT pts.


Uncontrolled gout pts (serum uric acid [sUA]≥7mg/dL, ULT failure/intolerance, ≥1 gout symptom) received pegloticase (biweekly 8mg infusion) and blinded oral MTX (15mg/wk) or PBO (2:1 randomization) following a 2-wk MTX tolerance test and 4-wk blinded MTX/PBO Run-in (eGFR<40ml/min/1.73m2 excluded). Baseline eGFR was measured before MTX exposure (Wk -6). Mean (SE) change from baseline (CFB) in eGFR was examined by treatment and baseline eGFR status (<60 and ≥60ml/min/1.73m2). Analyses were performed on all randomized pts (ITT).


100pts were randomized to pegloticase+MTX (56±13 yrs, 91% men, eGFR=68.9±18.0ml/min/1.73m2) and 52pts to pegloticase+PBO (53±12yrs, 85% men, eGFR=71.1±17.6ml/min/1.73m2). eGFR was stable during MTX/PBO Run-in and after pegloticase initiation (Day1) in both treatment groups (Figure). At Wk24, eGFR CFB was +5.3±1.3 and +4.3±2.3ml/min/1.73m2 in the MTX (N=70; 69responders) and PBO (N=19, 19responders) groups, respectively. eGFR CFB at Wk24 did not differ between eGFR<60 and ≥60 groups in MTX (+4.1±2.4 [N=27], +6.3±1.7 [N=43] ml/min/1.73m2 respectively) or PBO (+2.5±5.6 [N=7],+7.8±4.1 [N=12] ml/min/1.73m2 respectively) pts (both p≥0.48).


eGFR did not appear to decrease after oral MTX initiation when administered as co-therapy with pegloticase. This was true for pts with and without pre-therapy eGFR <60ml/min/1.73m2. These findings suggest MTX co-therapy did not negatively impact renal function in MIRROR RCT trial participants.


  • Commercial Support – Horizon Therapeutics plc